PPARG and non-small cell lung carcinoma: A novel PPARγ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone, decreased the viability of NSCLC cells by the induction of PPARγ while having a minimal effect on SCLC cells [176].